HIV Vaccine Trial in Thai Adults
A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults
Sponsor: Armed Forces Research Institute of Medical Sciences, Thailand
This PHASE3 trial investigates HIV Infection and is currently completed. Armed Forces Research Institute of Medical Sciences, Thailand leads this study, which shows 11 recorded versions since 2003 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
May 2019 — Jun 2019 [monthly]
Completed PHASE3
-
Dec 2018 — May 2019 [monthly]
Completed PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Armed Forces Research Institute of Medical Sciences, Thailand
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- MCM Vaccines B.V.
- Mahidol University
- Ministry of Health, Thailand
- Royal Thai Army Medical Department
- The Emmes Company, LLC
- Tripler Army Medical Center
- U.S. Army Medical Research and Development Command
- United States Army Medical Materiel Development Activity
- VaxGen
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .